Clinical Trial Update: Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD) [Phase 2]

View source ↗

Summary

Phase 2 trial update on intravitreal LFG316 for wet age-related macular degeneration showing safety and efficacy data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Exudative Macular Degeneration
• Neovascular Age-related Macular Degeneration

Drugs mentioned

• LFG316

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Neovascular Age-elated Macular Degeneration (Wet AMD), Exudative Macular Degeneration | Phase 2 | Status: COMPLETED